Comparison

ASCO Guidelines vs Oncoscience Brasil

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

ASCO Guidelines

Access comprehensive cancer care guidelines and interactive tools to inform treatment decisions. This app supports healthcare providers, patients, and caregivers in implementing recommended cancer care options for various cancer types, aiming to improve the quality of care.

Highlights
  • Guideline recommendations for cancer care
  • Interactive treatment decision tools
  • Supports healthcare providers
  • Informs patients and caregivers
  • Covers various cancer types
  • Regularly updated content
Features
Read full description

The ASCO Guidelines app is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The ASCO app is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added.

About

Oncoscience Brasil

Features
Read full description

O OncoScience Brasil é um grupo formado por médicos de várias especialidades que atuam no manejo do câncer, para discussões de casos oncológicos no intuito de troca de informações e experiências. Através deste a aplicativo, a OncoScience permite a troca de experiências e discussões multidisciplinares sem as barreiras institucionais, com médicos de todo o Brasil. - Fórum de discussões é divido em 9 áreas oncológicas, onde os médicos podem divulgar um caso para ser discutido entre os membros Onsciencience. - Gravação dos eventos "Tumor Board" e "Masterclass". - Grupo para divulgação de vagas de emprego - Grupo para divulgação de estudos clínicos

Screenshots

ASCO Guidelines4 screens

Verdict

The call

The clearest difference is update cadence: Oncoscience Brasil at every 3 weeks against ASCO Guidelines's every 5 months. ASCO Guidelines's advantage is iOS requirement (10.0 vs 15.1). On price, ads, in-app purchases and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

UpkeepUpdate frequency

ASCO Guidelines ships an update every 5 months, Oncoscience Brasil every 3 weeks. The most recent releases landed on October 16, 2026 and October 3, 2026 respectively.

Scorecard2 real differences · 8 level
ASCO Guidelines versus Oncoscience Brasil: the parameters behind the verdict, then further details
ParameterASCO GuidelinesOncoscience Brasil
PriceFreeFree
Rating4.8 (257 ratings) — better—
Positive reviews57.1% of reviews—
Number of ratings257 — better—
Update frequencyEvery 5 monthsEvery 3 weeks — better
AdsNoNo
In-app purchasesNoNo
MonetizationFree—
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS10.0 — better15.1
Further details — not scored
Size411 MB391 MB
Age rating12+4+
DeveloperAmerican Society of Clinical OncologyONCOSCIENCE BRASIL EDUCACAO MEDICA E SAUDE LTDA

In-app purchases

None

ASCO Guidelines

No in-app purchases

None

Oncoscience Brasil

No in-app purchases

Questions

Is ASCO Guidelines free?
ASCO Guidelines is free to download, with no in-app purchases.
Is Oncoscience Brasil free?
Oncoscience Brasil is free to download, with no in-app purchases.
Do ASCO Guidelines or Oncoscience Brasil have ads?
Neither ASCO Guidelines nor Oncoscience Brasil shows ads.
Which is updated more often, ASCO Guidelines or Oncoscience Brasil?
ASCO Guidelines ships an update every 5 months, and Oncoscience Brasil every 3 weeks. Most recently, ASCO Guidelines was updated on October 16, 2026 and Oncoscience Brasil on October 3, 2026.

Other comparisons